Literature DB >> 28465124

A multiple reader scoring system for Nasal Potential Difference parameters.

George M Solomon1, Bo Liu2, Isabelle Sermet-Gaudelus3, Isabelle Fajac4, Michael Wilschanski5, Francois Vermeulen6, Steven M Rowe2.   

Abstract

BACKGROUND: Nasal Potential Difference (NPD) is a biomarker of CFTR activity used to diagnose CF and monitor experimental therapies. Limited studies have been performed to assess agreement between expert readers of NPD interpretation using a scoring algorithm.
METHODS: We developed a standardized scoring algorithm for "interpretability" and "confidence" for PD (potential difference) measures, and sought to determine the degree of agreement on NPD parameters between trained readers.
RESULTS: There was excellent agreement for interpretability between NPD readers for CF and fair agreement for normal tracings but slight agreement of interpretability in indeterminate tracings. Amongst interpretable tracings, excellent correlation of mean scores for Ringer's Baseline PD, Δamiloride, and ΔCl-free+Isoproterenol was observed. There was slight agreement regarding confidence of the interpretable PD tracings, resulting in divergence of the Ringers and Δamiloride, and ΔCl-free+Isoproterenol PDs between "high" and "low" confidence CF tracings.
CONCLUSION: A multi-reader process with adjudication is important for scoring NPDs for diagnosis and in monitoring of CF clinical trials.
Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CFTR; Clinical trial outcomes; Nasal Potential Difference

Mesh:

Substances:

Year:  2017        PMID: 28465124      PMCID: PMC5671639          DOI: 10.1016/j.jcf.2017.04.011

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  28 in total

1.  A Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose Trial.

Authors:  Eric W F W Alton; A Christopher Boyd; David J Porteous; Gwyneth Davies; Jane C Davies; Uta Griesenbach; Tracy E Higgins; Deborah R Gill; Stephen C Hyde; J Alastair Innes
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

2.  Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey.

Authors:  Lutz Naehrlich; Manfred Ballmann; Jane Davies; Nico Derichs; Tanja Gonska; Lena Hjelte; Silke van Konigsbruggen-Rietschel; Teresinha Leal; Paola Melotti; Peter Middleton; Burkhard Tümmler; Francois Vermeulen; Michael Wilschanski
Journal:  J Cyst Fibros       Date:  2013-09-07       Impact factor: 5.482

3.  An international randomized multicenter comparison of nasal potential difference techniques.

Authors:  George M Solomon; Michael W Konstan; Michael Wilschanski; Joanne Billings; Isabelle Sermet-Gaudelus; Frank Accurso; François Vermeulen; Elina Levin; Heather Hathorne; Ginger Reeves; Gina Sabbatini; Aubrey Hill; Nicole Mayer-Hamblett; Melissa Ashlock; John Paul Clancy; Steven M Rowe
Journal:  Chest       Date:  2010-05-14       Impact factor: 9.410

4.  Nasal potential difference measurements to assess CFTR ion channel activity.

Authors:  Steven M Rowe; John Paul Clancy; Michael Wilschanski
Journal:  Methods Mol Biol       Date:  2011

5.  A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis.

Authors:  M R Knowles; K W Hohneker; Z Zhou; J C Olsen; T L Noah; P C Hu; M W Leigh; J F Engelhardt; L J Edwards; K R Jones
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

6.  Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis.

Authors:  T Hofmann; M J Stutts; A Ziersch; C Rückes; W M Weber; M R Knowles; H Lindemann; R C Boucher
Journal:  Am J Respir Crit Care Med       Date:  1998-06       Impact factor: 21.405

7.  Measurements of transepithelial electric potential differences in the trachea and bronchi of human subjects in vivo.

Authors:  M R Knowles; W H Buntin; P A Bromberg; J T Gatzy; R C Boucher
Journal:  Am Rev Respir Dis       Date:  1982-07

8.  Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo.

Authors:  M R Knowles; J L Carson; A M Collier; J T Gatzy; R C Boucher
Journal:  Am Rev Respir Dis       Date:  1981-10

9.  Increased nasal potential difference and amiloride sensitivity in neonates with cystic fibrosis.

Authors:  C W Gowen; E E Lawson; J Gingras-Leatherman; J T Gatzy; R C Boucher; M R Knowles
Journal:  J Pediatr       Date:  1986-04       Impact factor: 4.406

10.  Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.

Authors:  Frank J Accurso; Steven M Rowe; J P Clancy; Michael P Boyle; Jordan M Dunitz; Peter R Durie; Scott D Sagel; Douglas B Hornick; Michael W Konstan; Scott H Donaldson; Richard B Moss; Joseph M Pilewski; Ronald C Rubenstein; Ahmet Z Uluer; Moira L Aitken; Steven D Freedman; Lynn M Rose; Nicole Mayer-Hamblett; Qunming Dong; Jiuhong Zha; Anne J Stone; Eric R Olson; Claudia L Ordoñez; Preston W Campbell; Melissa A Ashlock; Bonnie W Ramsey
Journal:  N Engl J Med       Date:  2010-11-18       Impact factor: 176.079

View more
  2 in total

1.  Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD).

Authors:  George M Solomon; Inez Bronsveld; Kathryn Hayes; Michael Wilschanski; Paola Melotti; Steven M Rowe; Isabelle Sermet-Gaudelus
Journal:  J Vis Exp       Date:  2018-09-13       Impact factor: 1.355

Review 2.  Research advances in molecular mechanisms underlying the pathogenesis of cystic fibrosis: From technical improvement to clinical applications (Review).

Authors:  Tao Wei; Hongshu Sui; Yanping Su; Wanjing Cheng; Yunhua Liu; Zilin He; Qingchao Ji; Changlong Xu
Journal:  Mol Med Rep       Date:  2020-10-16       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.